Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BCA101 |
Synonyms | |
Therapy Description |
BCA101 is a bifunctional antibody that targets both EGFR and TGFB and leads to inhibition of downstream signaling, which may lead to inhibition of tumor cell proliferation and activation of anti-tumor immune response (PMID: 37074042). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BCA101 | BCA-101|BCA 101 | EGFR Antibody 60 TGFB (Pan) Antibody 5 | BCA101 is a bifunctional antibody that targets both EGFR and TGFB and leads to inhibition of downstream signaling, which may lead to inhibition of tumor cell proliferation and activation of anti-tumor immune response (PMID: 37074042). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF act mut | colorectal cancer | sensitive | BCA101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with BCA101 resulted in a tumor growth inhibition of 31% compared to 8% with Erbitux (cetuximab) in a BRAF-mutant colorectal cancer cell line and human peripheral blood mononuclear cells coimplantation xenograft model (PMID: 37074042). | 37074042 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |